Month: February 2021

Revenue Increased 7% Year-Over-YearNon-Prostate Brachytherapy Revenue Increased 92% Year-Over-YearRICHLAND, Wash., Feb. 09, 2021 (GLOBE NEWSWIRE) — Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the second quarter fiscal 2021 ended December 31, 2020.Revenue for the second quarter of fiscal 2021 grew 7% to $2.36 million versus $2.21 million in the prior year comparable period. The company’s core prostate brachytherapy revenue declined 4% versus the second quarter of fiscal 2020 as procedure volumes continued to be impacted by decreased prostate cancer screenings throughout 2020 as a result of COVID-19. Prostate brachytherapy represented 80% of total revenue for the second quarter...

Increases facility by $150 million and extends it to 2026RARITAN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) — Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (“Ortho”), one of the world’s largest pure-play in vitro diagnostics companies, today announced that certain of its subsidiaries successfully amended their June 30, 2014 credit agreement (the “Credit Agreement”) on February 5, 2021.The amendment increases the revolving credit facility under the Credit Agreement by $150 million to an aggregate amount of $500 million and extends the maturity date to February 26, 2026, provided that such date may be accelerated subject to certain circumstances.The Company has filed an 8-K with the Securities and Exchange Commission with more information regarding the Amended Credit Agreement.About Ortho Clinical DiagnosticsOrtho...

NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) — PennantPark Floating Rate Capital Ltd. (NASDAQ: PFLT) (TASE: PFLT) announced today financial results for the first fiscal quarter ended December 31, 2020.HIGHLIGHTSQuarter ended December 31, 2020($ in millions, except per share amounts)CONFERENCE CALL AT 10:00 A.M. ET ON FEBRUARY 10, 2021PennantPark Floating Rate Capital Ltd. (“we,” “our,” “us” or the “Company”) will host a conference call at 10:00 a.m. (Eastern Time) on Wednesday, February 10, 2021 to discuss its financial results. All interested parties are welcome to participate. You can access the conference call by dialing toll-free (800) 239-9838 approximately 5-10 minutes prior to the call. International callers should dial (323) 794-2551. All callers should reference conference ID #2336989 or PennantPark Floating Rate Capital Ltd....

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) — Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the closing of its previously announced initial public offering of 9,828,017 shares of its common stock, plus an additional 1,474,202 shares sold pursuant to the full option exercised by the underwriters, at a price to the public of $18.00 per share. The aggregate gross proceeds to Vor from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Vor, were approximately $203.4 million. The shares began trading on the Nasdaq Global Market on Friday, February 5, 2021 under the ticker symbol “VOR”.Goldman Sachs & Co. LLC, Evercore ISI,...

MCLEAN, Va., Feb. 09, 2021 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) has priced a new offering of Structured Pass-Through Certificates (K Certificates), which includes a class of floating rate bonds indexed to the Secured Overnight Financing Rate (SOFR). The approximately $942 million in K Certificates (K-F99 Certificates) are expected to settle on or about February 19, 2021. The K-F99 Certificates are backed by floating-rate multifamily mortgages with 10-year terms, which are SOFR-based.K-F99 PricingDetailsCo-Lead Managers and Joint Bookrunners: Citigroup Global Markets Inc. and Goldman Sachs & Co. LLCCo-Managers: CastleOak Securities, L.P., J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Oppenheimer & Co. Inc.Related LinksThe K-F99 preliminary offering circular supplement: http://www.freddiemac.com/mbs/data/kf99oc.pdfFreddie...

BASKING RIDGE, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) — Verizon Business announced today they are working with Zyter®, a leading digital health and IoT-enablement platform, to help improve sports and entertainment venue operations while delivering a smarter, more immersive fan experience.Zyter® ThermalAlert, an award-winning thermal imaging platform, can automatically monitor the temperatures of fans as they walk into a venue. Paired with the high bandwidth, low latency and massive computing power of Verizon 5G Ultra Wideband and 5G Edge, the process can be streamlined for quicker entry, fewer choke points and less congestion compared to manual solutions utilizing in-person, handheld temperature scanners.“Zyter’s tools built on Verizon’s 5G network and MEC technology can make the return to venues of all kinds smoother and more efficient...

Infant Bacterial Therapeutics AB today announces that the Japan Patent Office has issued a decision to grant a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of feeding tolerance in preterm infants.The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications for the invention are currently pending in additional important future markets including the US and Europe. This patent further increases the existing protection of IBTs drug candidate IBP-9414 for which both Orphan Drug Exclusivity and biological data protection have been granted in the USA and EU. The Japanese patent expires in 2036...

Infant Bacterial Therapeutics AB (IBT) meddelar idag att det Japanska Patentverket beslutat utfärda ett godkännande för patentet: “A method of activating lactic acid bacteria”, vilket omfattar formuleringar av Lactobacillus reuteri inklusive IBP-9414. IBP-9414 är den läkemedelskandidat IBT utvecklar i fas III för förebyggande av nekrotiserande enterokolit hos prematura spädbarn och för förbättrat födointag hos dessa barn.Uppfinningen omfattar ett unikt sätt att aktivera bakterien och patentansökningar behandlas samtidigt i flera viktiga framtida marknader, inklusive USA och EU. Patentet styrker det existerande skyddet för IBTs läkemedelskandidat IBP-9414 för vilken både särläkemedelsstatus och dataskydd för biologiska produkter beviljats i USA och EU. Det Japanska patentet löper till 2036. IBP-9414 avses att marknadsföras i Japan när...

SCOTTSDALE, Ariz., Feb. 09, 2021 (GLOBE NEWSWIRE) — On Tuesday, February 16, 2021, AMMO, Inc. (NASDAQ: POWW) will host a conference call to review fiscal third quarter financial results.The conference call and audio-only webcast will begin at 4:30 p.m. EST on Tuesday, February 16, 2021. To participate in the conference call, please join by dialing 1-877-407-0789 (domestic), 1-201-689-8562 (international), or via webcast (http://public.viavid.com/index.php?id=143495) at least 5-10 minutes prior to the scheduled start and follow the operator’s instructions. When requested, please ask for “AMMO, Inc. Fiscal Third Quarter 2021 Earnings Call.”About AMMO, Inc.With its corporate offices headquartered in Scottsdale, Arizona. AMMO, Inc. (the “Company and/or AMMO”) designs and manufactures products for a variety of aptitudes, including law...

CALGARY, Alberta, Feb. 09, 2021 (GLOBE NEWSWIRE) — Marksmen Energy Inc. (“Marksmen” or the “Company”) (TSXV: MAH) (OTCQB: MKSEF) announces that it has completed the second and final closing of its previously announced non-brokered private placement of units (the “Units”) of Marksmen (the “Offering”) which was increased pursuant to the Company’s news release dated February 1, 2021. The Company issued 12,575,000 Units at a price of $0.04 per Unit for aggregate gross proceeds of $503,000, bringing the total aggregate gross proceeds raised under the Offering to the maximum of $600,000. Each Unit is comprised of one (1) common share (“Common Share”) and one (1) share purchase warrant (“Warrant”) of Marksmen. Each whole Warrant entitles the holder thereof to purchase one Common Share at a price of $0.07 per share expiring two (2)...